Bionomics Expands Aussie Phase II Trials For Cancer Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Bionomics says it has added a dozen new sites for conducting Phase II trials of its BNC105 drug for treating mesothelioma, a lung cancer often caused by exposure to asbestos